Evidence map›Paper›PMID 22395732›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012

Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.

Stephanie J Klenotich, Mariel P Seiglie, Matthew S McMurray, Jamie D Roitman, Daniel Le Grange, Priya Dugad, Stephanie C Dulawa

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
6.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Animal Models for Anorexia Nervosa-A Systematic Review.Frontiers in human neuroscience · 2020
    Pooled it
  2. Pooled it
  3. Salience network and olanzapine in schizophrenia: implications for treatment in anorexia nervosa.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015
    Trial
  4. Article
  5. Article
  6. Neural circuits regulating activity-based anorexia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Stephanie J KlenotichCommittee on Neurobiology, University of Chicago, Chicago, IL, USA.
Mariel P Seiglie
Matthew S McMurray
Jamie D Roitman
Daniel Le Grange
Priya Dugad
Stephanie C Dulawa
University of Chicago · USUniversity of Illinois Chicago · US

Funding

TRAINING IN NEURAL SYSTEMST32GM007839 · NIGMS · UNIVERSITY OF CHICAGO · PI MASON, PEGGY · 1985 to 2012
$4.2M
Mechanisms for 5-HTT control of PPI and perseverative behavior using mouse modelsR01MH079424 · NIMH · UNIVERSITY OF CHICAGO · PI DULAWA, STEPHANIE C · 2007 to 2011
$1.8M
2/2-Treatment of Adolescent BulimicsR01MH079979 · NIMH · UNIVERSITY OF CHICAGO · PI LE GRANGE, DANIEL · 2008 to 2012
$1.5M
Cortico-striatal signaling in risk preferenceR21DA027127 · NIDA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ROITMAN, JAMIE D. · 2010 to 2011
$385k
NIDA NIH HHS DA027127NIDA NIH HHS R21 DA027127NIGMS NIH HHS T32 GM007839NIGMS NIH HHS T32GM07839NIMH NIH HHS R01 MH079424NIMH NIH HHS R01MH079424NIMH NIH HHS R01 MH079979NIMH NIH HHS R01MH079979
6 · The paper itself

Abstract

Anorexia nervosa (AN) is an eating disorder characterized by extreme hypophagia, hyperactivity, and fear of weight gain. No approved pharmacological treatments exist for AN despite high mortality rates. The activity-based anorexia (ABA) phenomenon models aspects of AN in rodents, including progressive weight loss, reduced food intake, and hyperactivity. First, we optimized the ABA paradigm for mice. We compared mouse strains (Balb/cJ, A/J) for susceptibility with ABA, and evaluated the effects of different food access durations (2, 4, 6, 8, and 10 h) on ABA parameters. Balb/cJ mice exhibited significantly shorter survival time (days until 25% bodyweight loss) in the ABA paradigm compared with A/J mice. Furthermore, 6 h of food access reduced survival in mice housed with wheels without reducing survival in mice housed without wheels. We then evaluated the effects of chronic treatment with fluoxetine (4 weeks) or subchronic treatment with olanzapine (OLZ) (1 week) on ABA in BALB/cJ mice. OLZ (12 mg/kg/day) significantly increased survival and reduced food anticipatory activity (FAA). However, OLZ did not alter food intake or running wheel activity during ad-lib feeding (baseline) or restriction conditions, or in mice housed without wheels. Fluoxetine (18 mg/kg/day) increased food intake and reduced FAA, but did not alter survival. Here, we report for the first time that OLZ, but not fluoxetine, reduces ABA in mice. Our findings indicate further need for clinical investigations into the effects of OLZ, but not selective serotonin reuptake inhibitors, on core features of AN.

Indexed as

AnimalsAnorexiaBenzodiazepinesBody WeightDisease Models, AnimalDose-Response Relationship, DrugEatingFemaleFluoxetineMiceMotor ActivityOlanzapineRunningSelective Serotonin Reuptake InhibitorsSurvival RateBenzodiazepinesFluoxetineOlanzapineSelective Serotonin Reuptake Inhibitors

Identifiers

PMID22395732
PMCPMC3358753
OpenAlexW2045292276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.